Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Leu31Pro34-NPY is a synthetic peptide analog of neuropeptide Y (NPY) that acts as a potent and selective agonist for the neuropeptide Y receptor Y1 (NPY1R), with some cross-reactivity for Y4 and Y5 receptors. It is widely utilized as a pharmacological research tool to investigate the physiological roles of Y1 receptor signaling, including its involvement in anxiety, depression, post-traumatic stress disorder (PTSD), memory consolidation, vasoconstriction, and pancreatic beta-cell survival. In preclinical studies, Leu31Pro34-NPY has been shown to protect mouse pancreatic islets against cytokine-induced apoptosis and to prevent stress-induced depressive-like behaviors in animal models.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Leu31Pro34-NPY.